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The effect of the pineal indole hormone melatonin on the life span of mice, rats and fruit flies has been studied using various approaches. It has
been observed that in female CBA, SHR, SAM and transgenic HER-2/neu mice long-term administration of melatonin was followed by an
increase in the mean life span. In rats, melatonin treatment increased survival of male and female rats. In D. melanogaster, supplementation of
melatonin to nutrient medium during developmental stages produced contradictory results, but and increase in the longevity of fruit flies has been
observed when melatonin was added to food throughout the life span. In mice and rats, melatonin is a potent antioxidant both in vitro and in vivo.
Melatonin alone turned out neither toxic nor mutagenic in the Ames test and revealed clastogenic activity at high concentration in the COMET
assay. Melatonin has inhibited mutagenesis and clastogenic effect of a number of indirect chemical mutagens. Melatonin inhibits the development
of spontaneous and 7-12-dimethlbenz(a)anthracene (DMBA)- or N-nitrosomethylurea-induced mammary carcinogenesis in rodents; colon
carcinogenesis induced by 1,2-dimethylhydrazine in rats, N-diethylnitrosamine-induced hepatocarcinogenesis in rats, DMBA-induced
carcinogenesis of the uterine cervix and vagina in mice; benzo(a)pyrene-induced soft tissue carcinogenesis and lung carcinogenesis induced
by urethan in mice. To identify molecular events regulated by melatonin, gene expression profiles were studied in the heart and brain of melatonin-
treated CBA mice using cDNA gene expression arrays (15,247 and 16,897 cDNA clone sets, respectively). It was shown that genes controlling the
cell cycle, cell/organism defense, protein expression and transport are the primary effectors for melatonin. Melatonin also increased the expression
of some mitochondrial genes (16S, cytochrome c oxidases 1 and 3 (COX1 and COX3), and NADH dehydrogenases 1 and 4 (ND1 and ND4)),
which agrees with its ability to inhibit free radical processes. Of great interest is the effect of melatonin upon the expression of a large number of
genes related to calcium exchange, such as Cul5, Dcamkl1 and Kcnn4; a significant effect of melatonin on the expression of some oncogenesis-
related genes was also detected. Thus, we believe that melatonin may be used for the prevention of premature aging and carcinogenesis.
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According to the free radical theory of aging, various oxi-
dative reactions occurring in the organism (mainly in mitochon-
dria) generate free radicals as byproducts which cause multiple
lesions in macromolecules (nucleic acids, proteins and lipids),
leading to their damage and aging. This theory explains not only
the mechanism of ageing per se but also a wide variety of age-
associated pathology, cancer including. Recent evidence sug-⁎ Corresponding author. Tel.: +7 812 596 8607; fax: +7 812 596 8947.
E-mail address: aging@mail.ru (V.N. Anisimov).
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doi:10.1016/j.bbabio.2006.03.012gests that key mechanisms of both aging and cancer are linked
via endogenous stress-induced DNA damage caused by reactive
oxygen species [1–5].
Melatonin (N-acetyl-5-methoxy-tryptamine) is the main
pineal hormone synthesized from tryptophan, predominantly
during the night [6]. Melatonin is critical for the regulation of
circadian and seasonal changes in various aspects of physiology
and neuroendocrine function [6,7]. As age advances, the noc-
turnal production of melatonin decreases in animals of various
species, including humans [8,9]. The grafting of a pineal gland
from young donors into the thymus of old syngeneic mice or in
situ into pinealectomized old mice prolongs the life span of the
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extension is a hot topic for discussion [12–17]. There are a
number of reports showing the anticarcinogenic and antitumor
potential of melatonin [16,17].
In this work, the results of studies on the effect of melatonin
on reactive oxygen species generation, life span and tumori-
genesis in experimental animals are reviewed.
2. Melatonin as antioxidant
Since 1993, when melatonin was firstly identified as a free
radical scavenger [18] many papers have been published con-
firming the ability of melatonin to protect DNA from free radical
damage (Table 1). There is evidence that melatonin in vitro
directly scavenges
U
OH, H2O2, singlet oxygen (↑O2
U−), and
inhibits lipid peroxidation. Melatonin stimulates a number of
antioxidative enzymes including SOD, glutathione peroxidase,
glutathione reductase, and catalase. It has been shown that
melatonin enhances intracellular glutathione levels by stimulat-
ing the rate-limiting enzyme in its synthesis, γ-glutamylcysteine
synthase, which inhibits the peroxidative enzymes nitric oxide
synthase and lipoxygenase. There is evidence that melatonin
stabilizes microsomal membranes, thereby probably helping
them resist oxidative damage [19]. Melatonin has been shown to
increase the efficiency of the electron transport chain and, as a
consequence, to reduce electron leakage and the generation of
free radicals [20]. It was shown that melatonin reduced theTable 1
Effect of melatonin on free radical processes
Radical or reactive oxygen specimens,
enzyme
Effect of
melatonin
References
Reactive oxygen specimens
Hydroxyl radical (
U
OH) ↓ [18]
Singlet oxygen (↑O2) ↓ [21]
Hydrogen peroxide (H2O2) ↓ [29]
Nitric oxide (NO) ↓ [30]
Peroxyl radical (LOO
U
) ↓ [31]
ONOO− ↓ [32]
Products of oxidation
Malone aldehyde ↓ [33]
Ketodiene ↓ [34]
Diene conjugate ↓ [35]
Schiff's bases ↓ [35]
CO-derivatives of aminoacids ↑ [36]
8-oxyguanine ↓ [33]
8-hydroxy-2′-deoxyguanosine ↓ [37]
Enzymes of antioxidative defense system
Cu,Zn-superoxide dismutase (SOD) ↑ [38]
Catalase ↑ [29]
Glutathione peroxidase ↑ [39]
Glutathione reductase ↑ [40]
γ-Glutamylcystein synthase ↑ [41]
Glucoso-6-phosphate dehydrogenase ↑ [34]
Myeloperoxidase ↑ [34]
Prooxidant enzymes
Nitric oxide synthase ↓ [30]formation of 8-hydroxy-2′-deoxyguanosine, a damaged DNA
products, 60 to 70 times more effectively than some classic
antioxidants (ascorbate and α-tocopherol) [21]. Thus, melatonin
acts as a direct scavenger of free radicals with the ability to
detoxify both reactive oxygen and reactive nitrogen species,
indirectly increasing the activity of the antioxidative defense
systems [20–23]. However, although the majority of studies
confirm the antioxidant potential of melatonin, in some con-
ditions, it can be prooxidant [23–28].
3. Effect of melatonin on gene transcriptional activity
In addition to its primary roles (circadian rhythm transduction
and free radical scavenging), melatonin also serves as a potent
modulator of gene transcriptional activity. Clearly, the expres-
sion of melatonin receptors in tissues and cell types makes a
major impact upon selectivity of biological action of melatonin.
Spectrum of cell surface membrane receptors of melatonin
(including MT1 (Mel1a), MT2 (Mel1b), Mel1c (found in amphi-
bians, avians and fishes)) demonstrates (i) spatial/tissue-specific,
(ii) spatial/cell-specific and (ii) temporal (developmental) va-
riations, reflecting the overall complexity of the melatonin-
mediated signal transduction. Additionally, “melatonin-related”
cell surface membrane receptor (similar to known membrane
melatonin receptors, but unable to bind melatonin itself) and
nuclear receptors of melatonin (namely, RZR/RORα and
NR1F2 (RZR/RORβ)) are known to have diverse expression
profiles (ranging from ubiquitous to restricted), adding to the
complexity of signal transduction mediated by the pineal
hormone. It is believed that the existence of multiple melatonin
receptor isoforms ensures the selectivity to natural ligands, dif-
ferential regulation of the receptor expression (both temporal
(developmental) and special (in different tissues)), and selective
pathways for an intracellular signal transduction [42].
Over the course of last decade, conventional approaches have
allowed identification of a large number of genes, targeted by
melatonin centrally (in brain structures, most importantly in
suprachiasmatic nucleus (SCN) of the hypothalamus and in pars
tuberalis (PT) of the hypophysis) or in peripheral tissues.
Discovering the mechanisms of melatonin interaction with so-
called clock-genes (Per, Clock, Bmal and others) could be con-
sidered as one of the major achievements of these studies. It has
been hypothesized that melatonin mediate the photoperiodic
control of a season physiology via the phasing of expression of
clock-genes in the PT, with a length of the melatonin signal
decoded in target tissues in a form of the clock-gene expression
profile signatures (“internal coincidence model”; [43]). Being
rather complex and involving a number of regulatory and auto-
regulatory loops, close interaction of melatonin with clock genes
ensures the consistency of biological rhythms and precision of
photoperiod affect upon gene expression in melatonin-sensitive
(target) tissues.
Progress in a development of high-throughput technologies
(most importantly of DNA microarrays) have substantially in-
cremented the list of melatonin targets in peripheral tissues, and
have significantly improved our understanding of the mechan-
isms of it biological action. Numerous technological advances
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contain tens to over hundred thousand of spots of DNAmaterial,
thus reaching a truly genomic scale [44]. The principle of this
approach has been proved in a diversity of experiments. In one of
the first screening-oriented studies, the effect of melatonin
treatment upon gene expression in rat retina (retinal neurons and
retinal pigment epithelium (RPE)) was addressed using cDNA
microarray. Microarray-based screening of ∼8000 rat cDNA
clones have led to the identification of the limited group of genes
with expression in rat neural retina and RPE being changed
significantly by melatonin [45]. In neural retina, treatment with
melatonin had stimulated an expression of 6 and repressed an
expression of 8 genes, while in RPE cells 15 genes were up-
regulated and 2 were down-regulated. Among these, genes with
important physiological functions were present. For example,
melatonin had down-regulated gene expression of integrin and
integrin-associated protein-encoding genes in rat retina, while a
cyclic AMP response element binding protein (CREB) gene was
up-regulated in RPE. Importantly, many gene targets identified
were expressed sequence tags (ESTs) matching novel genes,
thus providing an invaluable hint for future insights into the
mechanisms of biological action of melatonin in retina. It should
be also mentioned that lists of melatonin targets in two closely
related retinal cell types were mutually exclusive: this un-
expected observation was further supported in further studies of
our own.
In first of the latter, we have employed an avowed NIA 15 K
cDNA microarray that contained over 15,000 mouse cDNA
clones representing about 11,000 individual gene products [46].
We have hypothesized that a short-term course of melatonin
treatment (for duration of 5 days) followed by RNA harvest
would allow us identifying gene which determine the initial
stages in the cascades of events resulting in carrying out vital
biological effects of melatonin. CBA mice of experimental
group were administered melatonin with drinking water ad libi-
tum, and after 5-day treatment total RNA purified from cardiac
tissue was used to synthesize isotope (33P)-labeled probes which
were subsequently hybridized to microarrays. Analysis of the
microarray data allowed us to identify a limited group of tran-
scripts (212, <1.4% of the clones screened) with significantly
altered cardiac gene expression [47]. Among these, 146 genes
were up-regulated and 66 down-regulated (ZRatio confidence
level=2.0), including such genes as Cop1, Wnt4 and Stk11 (up-
regulated) and Ubc2e and Spi4 (down-regulated), all of which
have important biological roles. Using an established system for
functional categorization of genes expressed in cardiovascular
system [48], we have discovered that although melatonin indeed
affects the expression of a wide spectrum of genes, its primary
effectors are associated with the genes controlling the cell cycle,
adhesion, and transport. This finding is in agreement with the
established data on the effect of melatonin on cell proliferation,
apoptosis, and adhesion [49], as well as with numerous earlier
studies based on the low-throughput approaches. Notably, mela-
tonin have also demonstrated a pronounced effect on the expres-
sion of genes related to oncogenesis (e.g., Mybl1, Rasa1, Mllt3
and Enigma homolog 2) and calcium metabolism (Kcnn4 and
Dcamkl1).Importantly, we have also detected a significant effect of
melatonin upon expression of some mitochondrial genes:
namely, the genes encoding 16S ribosomal RNA (mt-Rnr2),
cytochrome c oxidase subunits I and III (mt-Co1, mt-Co3) and
NADH dehydrogenase 1 (mt-Nd1) (all up-regulated) and ATP
synthase subunit 6 (mt-Atp6; down-regulated). This finding
supports previous observations of the direct effect of mela-
tonin upon the expression of mitochondrial genome-encoded
genes in the brown adipocytes of Siberian hamster. Although
the approach used in that study have allowed identification of
only one mitochondrial gene (cytochrome b, mt-Cytb) as a
target of melatonin, it was further suggested in the same study
that melatonin may act on the entire mitochondrial genome [50].
Justifiably, the expression of mitochondrial genome-encoded
genes is very high in tissues with biological function directly
associated with continuous contraction of muscle fibers and/or
transmembrane ion transport [51,52]. Alterations in the amount
of mitochondrial transcripts and, subsequently, in the volume of
energy produced in mitochondria by oxidative phosphorylation
(OXPHOS) are therefore critical for organ function.
To study the effect of melatonin upon gene expression in
mouse brain, we have used an updated NIA 17K cDNA micro-
array, representing a reformatted combination of NIA 15K [46]
and NIA 7,4K libraries [53] containing nearly 17,000 mouse
cDNA clones representing more than 12,000 individual gene
products. A limited group of transcripts (38, < 0.3% of the clones
screened) had demonstrated altered expression [54]. Among
these, 5 genes were up-regulated and 33 down-regulated (ZRatio
confidence level=1.5). Examples include such genes as Irf3 and
Tlk2 (down-regulated); notably, biological function of the last is
related to CREB protein. As it have been observed in the earlier
study by Wiechmann [45], nearly independent set of melatonin
gene targets was identified in the tissue constituted by the diverse
cell types. Importantly, we were able to identify only one tran-
script with expression changed by melatonin in both heart and
brain: notably, it was encoded bymitochondrial genome (NADH
dehydrogenase 4; mt-Nd4). Comparative analysis of melatonin
effect upon gene expression in mouse heart and brain thus
supports observations on some tissue-specific biological effects
of the melatonin signaling system [55] and further points out
the potential importance of mitochondrial genes in biological
actions of melatonin in target tissues.
4. Effects of melatonin on mutagenesis
There is evidence of an age-related accumulation of spon-
taneous mutations in somatic and germ cells [56,57]. The
accumulation with age of some spontaneous mutations or muta-
tions evoked by endogenous mutagens can induce genome
instability and, hence, increases the sensitivity to carcinogens
and/or tumor promoters. It has been shown that clonally ex-
panded mtDNA mutations accumulate with age in normal
human tissues [58]. The finding that deleted mtDNA accumu-
lated in human muscle tissue as well as evidence for partially
duplicated mtDNA in aged human tissues [59] allow us to
suggest the important role of clonal expansion of mutant mtDNA
in the age-related increase of systemic oxidative stress in the
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mutations frequency with advancing age was found in some
normal and malignant tissues [61,62]. Simpson [63] suggests
that the aging human body accumulates enough mutations to
account for multistep carcinogenesis by the selection of pre-
existing mutations.
Melatonin has been found to inhibit X-ray induced muta-
genesis in human and mouse lymphocytes in vitro [64–66], to
reduce Cis-platinum-induced genetic damage in the bone mar-
row of mice [67], to decrease hepatic DNA adduct formation
caused by safrole in rats [68] and to protect rat hepatocytes from
chromium(VI)-induced DNA single-strand breaks in vitro [69].
We studied the effect of melatonin on the induction of chro-
mosome aberrations and sperm head anomalies in mice treated
with cyclophosphamide, 1,2-dimethylhydrazine and N-nitro-
somethylurea and found that melatonin potently inhibited the
mutagenicity of these carcinogens [70].
Since melatonin can protect cells directly as an antioxidant
[71], and indirectly through receptor-mediated activation of
antioxidative enzymes, we applied the Ames test system in vitro
[72]. Some of the mutagens used are known to damage DNA
through several mechanisms. In order to test these mutagens, we
tried to use different strains of Salmonella typhimurium that
turned out to be able to detect different mechanisms, in a non-
toxic range of concentrations, using the preincubation assay. The
strains TA 97 and TA 98 are sensitive to different frameshift
mutagens. TA 100 detects G-A base-pair substitutions, while TA
102 is sensitive to mutagens damaging A–T pairs, mainly
through free radicals formation, and cross-linking agents [72].
We supposed that melatonin, being an antioxidant, could affect
mutational events which result from oxidative damage and so
could inhibit revertant colony formation in the stain TA 102
specially designed to detect this type of lesions. Thus, melatonin
alone turned out neither toxic nor mutagenic in the Ames test.
The Single Cell Gel Electrophoresis assay (SCGE assay or
COMET assay) was used for the evaluation of the clastogenic
effect of melatonin and it was shown that it had clastogenic
activity at the highest concentration tested (100 μM) in the
SCGE assay [72].
As oxidative mutagens we used DMH, bleomycin (with S9-
mix) and mitomycin C (without S9-mix) which are believed to
generate oxygen radical species [73,74]. Furthermore, mitomy-
cin C acts as a bifunctional alkylating agent [75]. Additionally,
we tested eight other intercalating and alkylating agents both
direct-acting and those requiring metabolic activation. The 12
mutagens used were 7, 12-dimethylbenz(a)anthracene (DMBA),
benzo(a)pyrene (BP), 2-aminofluorene (AF), 1,2-dimethylhy-
drazine (DMH), bleomycin, cyclophosphamide (CP), 4-nitro-
quinoline-N-oxide (NQO), 2,4, 7-trinitro-9-fluorenone (TNF),
9-aminoacridine (AA), N-nitrosomethylurea (NMU), mitomy-
cin C and sodium azide tested in the absence or presence of S9
mix. In four Salmonella typhimurium tester strains, TA 97, TA
98, TA 100 and TA 102, melatonin significantly reduced the
mutagenicity of chemicals which require S9 activation. In the
SCGE assay performed on CHO cells, preincubation with mela-
tonin led to a strong inhibition of the clastogenic activities of
DMBA and CP, and to a lesser extent with BP and NMU. Withmitomycin C, melatonin exacerbated responses in both tests. It
should be noted that melatonin was effective as an antimutagen
only at extremely high doses (0.25–2 μmol/plate) [72]. The
modifying activity of melatonin was not related to the mecha-
nism of action of the mutagens, i.e., frameshift mutations or
base-pair substitutions. As melatonin displays its protective
effect towards promutagens only, we speculate that it can exert
its activity on the metabolic activation process, perhaps by inhi-
biting the cytochrome P 450-dependant mono-oxygenase en-
zyme system of S9-mix. Another explanation of the S9mediated
properties of melatonin could be that the antimutagenic effect
results from metabolites of melatonin, such as 6-hydroxymela-
tonin. 6-hydroxymelatonin was found to be able to inhibit the
thiobarbituric-induced lipoperoxidation in mouse brain homo-
genates, which was imputed to the production of oxygen free
radicals [76].
Generally, the results of the SCGE assay are in accordance
with those of the Ames test. Melatonin modulates the
clastogenicity of DMBA, BP and cyclophosphamide. Compared
to the data obtained in the Ames test, melatonin inhibited the
clastogenicity of the chemicals at lower concentrations (0.1–
1 nM). In combination with mitomycin C a significant, dose-
related, exacerbating effect of melatonin has been observed in
both tests [72]. The available data shows that melatonin may
play an important role in defending cells from DNA damage
induced, not only by oxidative mutagens, but also by different
alkylating agents.
5. Effect of melatonin on apoptosis
In a series of studies it was shown that melatonin inhibits
apoptosis in cells of the brain, induced by reactive oxygen
species (ROS) [28], kainate [77], amyloid β-peptide, related to
Alzheimer disease [78], neuromediators [79] and neurotoxins
[80], but not by N-methyl-D-aspartate [77], staurosporine or
neurotoxin ethylcholinazyridine [81]. It was suggested that the
protective effect of melatonin on neurocyte apoptosis depends
on the model used and is not mediated by caspase-dependent
programmed cell death, but involves prevention of glycolysation
derivative-induced necrosis [81]. In contrast, exaggeration of
neuronal damage by melatonin was observed in native cultures
as well as after induction of apoptosis [81]. Melatonin supple-
mentation suppresses NO-induced apoptosis via induction of
Bcl-2 expression in immortalized pineal PGT-β cells [82]. A
similar pathway of inhibitory effects of melatonin on apoptosis
induced by ischemic neuronal injury has been determined [83].
Low doses of melatonin (10−7–10−9 M) inhibit apoptosis in
both dexamethasone-treated, cultured thymocytes and the intact
thymus [84]. This effect of melatonin was mediated by its
inhibitory influence on proliferation of thymocytes [85]. Long-
term (over 8 months) administration of melatonin at a daily dose
of 40–50 μg per mouse prevents thymic involution in very old
animals, an effect brought about by the inhibitory action of
melatonin on dexamethazone-induced apoptosis in thymocytes
and splenocytes [86]. The administration of melatonin to mice in
the drinking water (15 mg/l) for 40 days also attenuated the
apoptotic thymocyte death caused by free radicals and
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vitro and in vivo studies demonstrated an inhibitory effect of
melatonin on apoptosis in the thymus.
The administration of melatonin in the drinking water
(20 mg/l) during the dark phase to rats exposed to 1,2-dime-
thylhydrazine failed influence an apoptotic index in normal
colon mucosa but significantly (by 1.8 times) inhibited it in
colon tumors [88]. Treatment with the potent hepatocarcinogen
aflatoxin B1 leads to direct or indirect caspase-3 activation and
consequently to apoptosis in the rat liver. Melatonin treatment
enhances the rat hepatic antioxidant/detoxification system,
which consequently reduces the apoptotic rate and necrobiotic
changes in the liver [89].
6. Effect of melatonin on life span and longevity in rodents
Effects of melatonin on life span in mice and rats have been
discussed recently [15,16]. In Table 2, we summarized availableTable 2
Summary of experiments on the effect of melatonin on life span and spontaneous tu
Strain Sex Nos. of
mice C/M
Age at the
start of
treatment,
months
Treatment with melatonin
Balb/c Female 26/12 15 10 mg/l in night drinking water
Balb/c Male 50/50 18 10 mg/l in night drinking water
C57BL/6 Male &
female
25/45 1.5 2.5 mg/mouse s.c. twice a
weeks×5 months
C57BL/6 Male &
female
29/57 1.5 2.5 mg/mouse s.c. twice a
weeks×2.5 months
CC57Br Male &
female
26/57 1.5 2.5 mg/mouse s.c. twice a
weeks×2.5 months
C57BL/6J Male 10/10 19 10 mg/l in night drinking water
C57BL/6 Male 20/15 19 10 mg/l in night drinking water
C57BL/6 Male 1:20/20 18 11 ppm (68 μg/kg) with lab
chow ad libitum
2:7/13
3:38/30
CBA Female 50/50 6 20 mg/l in night drinking water
C3H Male 20/20 1 2.5 mg/kg/day in night drinking
waterFemale 20/20 8
C3H/He Female 14/15 12 10 mg/l in night drinking water
C3H/Jax Female 16/39 3 weeks 25–50 mg/mouse/day with
drinking water
HER-2 /neu Female 30/27/22 2 2.5 mg/kg/day in night drinking
water 5 days/monthly or constantl
NOD Female 25/30 1 4 mg/kg s.c. at 4:30 PM, 5 times
a weeks, 4–38 weeks
NOD Female 29/17 1 10 mg/l in night drinking water,
5 times a week, 4–38 weeks
NZB Female 10/10 4 10 mg/l in night drinking water
NZB/W Female 15/15/15 8 2–3.5 mg/kg s.c. daily at
8–10 h (M1) or at 17–19 h
(M2)×9 month
SAMP-1 Female 20/20 3 20 mg/l in night drinking water
SAMR-1 Female 10/12 3 20 mg/l in night drinking water
SHR Female 50/50/50 3 2 or 20 mg/l in night drinking
water
Note. C=control group; M=melatonin-treated group; MLS=maximum life span;
SAMP-1=senescence accelerated mouse-prone; SAMR-1=senescence accelerateddata on survival and tumor incidence in mice exposed to long-
term treatment with melatonin.
Melatonin did not induce malignancies in male C57BL/6
mice when administered at 10 mg/l (1.5–2.0 mg/kg) in the night
drinking water from 19 months [10,94]. Lipman et al. [95]
observed lymphomas in 77.9% of male C57BL/6 mice that
received melatonin with food (11 ppm or 68 μg/kg) from the age
of 18 months and survived to a 50% mortality (26.5 months). In
controls only 28.6% of mice developed lymphomas. Leukemia
was detected in 70–98% of C57BL/6 mice and 78% of CC57Br
mice (both males and females) treated subcutaneously with
melatonin at a dose of 2.5 mg/mouse (∼ 80 mg/kg) twice a week
for of 2.5–5 months [92,93]. Thus, being administered in sig-
nificantly high dose (about 80 mg/kg) melatonin induced lym-
phomas and leukemias in C57BL/6 mice. At low dose (from
68 μg/kg to 1.5–2.0 mg/kg) it induced them only in one small
group (7 mice). In a previous our study with CBA mice, mela-
tonin given in night drinking water in an interrupted (course)mor incidence in mice
Age at the end
of observation
Effects of melatonin on References
Mean life span Tumor
incidence
ND +18% No data [90]
ND Shift to right of the
survival curve
No data [91]
22 months −13% Increases [92]
22 months −20.6% Increases [93]
22 months −12% Increases [93]
ND + 20% No data [94]
ND +17% No data [10]
1: 24 months No effect 1: No effect; [95]
2: 50% survival 2: Increases;
3: died <2 years 3: No effect
ND +5% Increases [96]
23 months +20% No data [97]
27 months No effect
ND No effect Increases [10]
12 months No data Decreases [98]
y
ND M1: No effect; M2: −13% M1: No effect;
M2: Decreases
[99]
50 weeks C:32% survivors No data [100]
M:90% survivors
50 weeks +17% No data [100]
20 months Survivors: C:0; M: 40% No data [10]
34 weeks Survivors: C: 20%;
M1: 60%; M2: 60%
No data [101]
ND No effect No effect [102]
ND −11% No effect [102]
ND No effect;
M1, M2: +3 months. MLS
M1: ↓ 1.9-fold [103]
M2: No effect
ND=animals were survived until natural death; NOD=non-obese diabetic;
mouse-resistant.
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genic. Lymphomas and lung adenocarcinomas developed in
CBAmice treated with melatonin whereas no such malignancies
developed in controls [96]. In female SHR mice, melatonin
given approximately in the same dose (20 mg/l; 2.7–3.3 mg/kg)
failed significantly increase the total incidence of tumors or
tumors of any localization [103]. Strain differences in suscep-
tibility to chemical carcinogens are well known.
There is one strong critical comment on results of long-term
experiments with melatonin in mice. It was claimed that murine
strains used in some studies do not synthesize melatonin as a
result of a genetic defect (BALB/c, NZB, and C57BL/6) [104].
Later it was shown that the pineal gland did produce melatonin
in the above-mentioned mouse strains with genetic defects, but
the production night peak was very short, so its presence was
difficult to detect [100]. It is worthy to note that the major signal
transduction cascades in the pineal gland did not differ between
melatonin-proficient C3H mice and melatonin-deficient C57BL
mice [105].
Thus, with exception of the results of Romanenko's studies,
which used a very big dose of the compound, being administered
into mice of various strains regardless the age of mice at start of
the treatment, and sex, melatonin increased life span in 12 from
20 experiments (60%) and has no effect in 8 experiments (40%)
(P>0.05). In males, 4 from 5 experiments resulted in the life
extension with melatonin, while in females, 8 experiments were
positive and 7 were negative. If the treatment was started early,
8 of 14 cases observed the increase in longevity and 6 had no
effect.
We believe that these discrepancies related mainly to the
variations and defects in experimental design and strain sus-
ceptibility to melatonin. In the majority of these studies the
number of mice per group was rather small (20 and less) that is
not sufficient for correct conclusion in long-term studies devoted
to the evaluation of effect on both longevity and carcinogenicity
[15,16]. It is worth to note that among 4 experiments, which
were conduced according to the standard protocol (50 animals
per group) 3 resulted in the increase of the life span under the
influence of melatonin.
In an experiment with male CD rats melatonin was given
with drinking water (4 mg/l) during the whole day starting at
11–13 months age during 16 months [106]. Additional groups
of rats received with drinking water melatonin antagonist M-
(1,4-dinitrophenyl)-5-methoxytryptamin (ML-23) at the dose of
0.4 mg/l or combination of melatonin and ML-23) in the same
doses. Observation was stopped when the age of rats was 26–
29 months. In the control group to this age survived 7 from 16
rats (44%), whereas in the group exposed to melatonin alone—
13 from 15 rats (87%). Surprisingly, in the group exposed to the
melatonin antagonist ML-23 survived 6 from 10 mice; and in
the group treated with combination of melatonin and ML-23-
survived 8 from 10 rats. Body weight was similar in all groups.
Five of seven rats from the control group revealed a pneumonia
at autopsy whereas in the group treated with melatonin there
were no cases of pneumonia. The serum level of testosterone
was 2.8 times higher in rats treated with melatonin as compared
to the controls. Authors believe that melatonin antagonist ML-23 induces chronic deprivation of melatonin receptors followed
by their hypersensitivity to the melatonin. It is worthy of note
that in this experiment was small number of animals per group
and the experiment was finished before natural death of all
animals.
Vinogradova and Shevchenko [107] administered melatonin
in the night drinking water (10 mg/l) to 50 female and 50 male
outbred LIO rats since the age of 3 months until natural death.
Survival of melatonin-treated animals was significantly higher
as compared with intact controls at the age of 2 years (80% and
57%, respectively, p<0.05). At the same time melatonin signi-
ficantly inhibits the development of spontaneous tumors both in
males and females as compared with the intact controls. The
treatment with melatonin slowed down of the age-related in-
crease in the incidence of irregular estrous cycles. There was
observed a normalization of age-related changes in activity of
antioxidative enzymes and antioxidant status of rats under the
treatment with melatonin [108].
7. Effect of melatonin on longevity in fruit flies
We have studied the effects of melatonin on longevity in the
D. melanogaster strain HEM [109]. Melatonin was added to the
nutrition medium (100 μg/ml) during the 2nd to 3rd age of
larvas. Exposure to melatonin was followed by a decrease in the
level of conjugated hydroperoxides and ketodienes in females.
Furthermore, melatonin failed to influence the activity of cata-
lase in males, whilst it was increased in females by 24%
(p<0.02) and Cu, Zn-superoxide dismutase (SOD) activity was
unaltered in both males and females. Melatonin did not influence
the life span of this strain of fruit fly.
The life span of D. melanogaster wild strain Canton-S was
studied under treatment with melatonin at a concentration of
800 mg/l [110]. The hormone was introduced into the nutrient
medium at the larvas stages. Five experiments with melatonin
have shown variable effects of melatonin on life span: the mean
life span in males varied from −10.0% to +18.5%, whereas in
females the range was +2.3% to 12.1%. An inverse correlation
was observed between the change in life span after melatonin
supplementation and the life span in the corresponding control
group. For a relatively low life span in the population from
which the control and experimental group were formed, the
geroprotector effect of melatonin was the most distinct; for a
relatively high life span, the effect of melatonin was either not
detected or appeared as a reduction in life span due to a toxic
effect.
The effect of melatonin on life span was studied also in
D. melanogaster Oregon wild strain [111]. Melatonin, added
daily to the nutrition medium at a concentration of 100 μg/
ml throughout the experiment, significantly increased the life
span of the flies. The maximum life span was 61.2 days in
controls and 81.5 days in the melatonin-fed group (+33.2%).
Relative to controls, the percentage of the melatonin-fed flies
was 19.3% in the onset of 90% mortality and 13.5% in
median life span. The authors have also shown that
melatonin treatment increased the resistance of fruit flies to
superoxide mediated toxicity of paraquat and to thermal
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span, it statistically significantly increases the longevity of
fruit flies.
8. Effect of melatonin on carcinogenesis
The role of the pineal gland in tumor development has been
under intensive study during the last years [112–115]. In cancer
patients the morphological signs of pineal function decrease and
disturbances in the circadian secretion pattern of the main hor-
mone of the pineal gland, melatonin, were observed [112–115].
For a variety of tumors their growth is accelerated in pinealec-
tomized animals. The inhibitory effect of melatonin is well estab-
lished in relation to mammary tumors [113,116–118] and colon
cancer [119,120]. There are few data on the effect of mela-
tonin on tumors of other localizations. In this section we will
review available data on anticarcinogenic effects of melatonin.
8.1. Melatonin and mammary carcinogenesis
The evidence of oncostatic action of melatonin on mammary
tumor growth was obtained both in in vitro and in vivo expe-
riments. MCF-7 human breast cancer cell line mostly used as a
model for study of melatonin effect in vitro [116–118]. This cell
lines originated from the pleural effusion of women with meta-
static breast carcinoma, and contains both estrogen and proges-
terone receptors. It was shown that a growth of MCF-7 cells is
estrogen dependent and estrogens regulate the levels of some
RNAs and proteins in them [116]. The inhibitory effect of
melatonin onMCF-7 cells was firstly observed by Blask andHill
[121]. A lot of experiments on effect of melatonin onMCF-7 cell
growth was reviewed recently by Cos and Sanchez-Barcelo
[116,117]. It was shown that melatonin, at physiological concen-
tration in a culture medium, inhibits cell proliferation and inva-
siveness of the cells, suppress mitotic activity of estradiol-17β
and EGF, thus blocks proliferation at stage G0/G1 of mitotic
cycle. Only those lines of MCF-7 and other breasts carcinoma
cell lines mammary which have estrogen receptors (T47D,
ZR75-1) have been shown susceptible to inhibitory effect of
melatonin [116–118,122,123]. Lemus-Wilson et al. [124]
observed inhibitory effect of melatonin on proliferative effect
of prolactin and human growth hormone on MCF-7 cells. There
is suggestion that melatonin suppress autocrine and paracrine
secretion of some growth factors (EGF, TGF-α, insulin, IGF-I
and II [125].
Anisimov et al. [126] have shown inhibitory effect of mela-
tonin on transplantable mammary carcinoma RSM in female
Ñ3ÍÀ mice. Melatonin was given subcutaneously in a daily dose
of 50 μg/mouse and 51% decrease of tumor size has been
observed.
According Hamilton and Sneddon [127], morning adminis-
tration of melatonin to rats was followed by the increase in the
incidence of mammary carcinomas induced byDMBA in female
rats. However it was shown in several experiments that the eve-
ning treatment with melatonin inhibits DMBA-induced mam-
mary carcinogenesis [128–134]. Melatonin also attenuated the
stimulating mammary carcinogenesis effect of pinealectomy[135]. Another mammary carcinogen, N-nitrosomethylurea
(NMU) was also used in experiments with melatonin. This
model has some advantages in comparison to DMBA-induced
carcinogenesis. In contrast to DMBA-induced mammary adeno-
carcinoma susceptible mostly to prolactin, the growth of NMU-
induced mammary carcinoma is more depend on the levels of
estrogens, that is more relevant to human breast carcinoma
[136]. In several studies have been observed inhibitory effect of
melatonin on NMU-induced carcinogenesis in mammary gland
of rats [129,137,138]. It is interesting that melatonin failed
reveal the dose-dependent inhibitory effect in this model. The
effect of melatonin was similar to those of estrogen antagonist
tamoxifen [67].
Subramanian and Kothari [139] reported a suppressive effect
of melatonin on the development of spontaneous mammary
carcinomas in female C3H/Jax mice treated from the age of
3 weeks until the age of 12 months. in female CBA mice,
administration of melatonin with night drinking water from the
age of 6 months failed change the incidence of spontaneous
mammary adenocarcinomas [140].
The oncostatic effects of melatonin on the mammary gland
have been studied in transgenic mice carrying the N-ras proto-
oncogene under the control of the MMTV-LTR [141]. Female
(4-week-old) virgin mice with positive transgenic pedigrees
were injected with melatonin (200 μg/mouse/ day, 5 times a
week) or vehicle late in the evening. After 5 months of
treatment, animals were sacrificed and the mammary glands
were dissected for whole mounts, histology, and immunohis-
tochemical analysis with a mouse monoclonal antibody specific
for N-ras protein. Mammary glands of control transgenic mice
showed different densities of hyperplastic alveolar nodules
(HANs) consisting primarily of dysplastic epithelial cells with
nuclear atypia and prominent nucleoli. The epithelial cells of
HANs showed a high expression of N-ras while no immunos-
taining was detected in the unaffected mammary parenchyma.
Only one (10%) of the control transgenic mice presented an
infiltrating ductal carcinoma with the neoplastic cells over-
expressing N-ras protein. The mammary glands of melatonin
treated mice had a lower density of HANs, absence of epithelial
dysplastic cells, and weak immunostaining of N-ras protein in
comparison to the vehicle-treated group. None of the melatonin
treated animals developed mammary carcinomas during the
observation period. The lymph nodes of the inguinal mammary
glands of all the vehicle-treated transgenic mice presented
hyperplasia and two animals even had lymphomas, whereas in
melatonin-treated animals there was less hyperplasia (two cases
were atrophic) and a lack of lymphomas. Authors conclude that
in the mammary glands of MMTV-LTR/N-ras transgenic female
virgin mice, melatonin reduces the incidence of HANs and the
expression of N-ras protein in focal hyperplastic lesions,
completely prevents the development of epithelial cell atypia
and mammary adenocarcinomas, and also reduces the hyper-
plasia of the mammary lymphoid tissue and prevents the
development of lymphomas.
Four-week-old TG.NK female mice with MMTV/c-neu
oncogene were gavaged with melatonin at 50, 100 or 200 μg/
kg dissolved in corn oil [142]. Melatonin delayed the appearance
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dose-related statistically significant negative trend for the inci-
dence of tumors.
The administration of melatonin during the night time signi-
ficantly decreased the incidence of mammary adenocarcinomas
in FVB/N female mice transgenic for oncogene HER-2/neu
[143]. Melatonin administration decreased the size of mammary
adenocarcinomas (p<0.05) and the incidence of lung metastases
(p<0.07) as compared with controls. In order to evaluate whe-
ther the decreased incidence of mammary tumors observed in
mice was due to an effect of melatonin on mammary gland, we
performed RT-PCR analysis for HER-2/neu gene expression in
the mammary tumors from mice. mRNA for HER-2/neu gene
was greatly expressed in saline treated mice whereas it was
significantly (2.5-fold) decreased in animals chronically treated
with melatonin [143].
8.2. Melatonin and colon carcinogenesis
We have studied the effect of melatonin on colon carcino-
genesis. Intestinal tumors induced in rats by 1,2-dimethylhy-
drazine (DMH) and its carcinogenic metabolites azoxymethane
(AOM) and methylazoxymethanol at present are the most
popular models used in experimental oncology to study various
aspects of the morphology, pathogenesis, prevention and treat-
ment of colorectal cancer [144]. It was shown that colon carci-
nomas induced by DMH are morphologically similar to human
colon tumors and, like other malignancies, a colon carcinoma
needs at least several stages (events) for development in bowel
mucosa.
Three-month-old male LIO rats were exposed to 5 or
15 weekly s.c. injections of 21 mg/kg DMH [145,146]. Part of
DMH-treated rats was given melatonin in tap water (20 μg/ ml)
at night time during the period of the carcinogen treatment. Rats
were sacrificed in 6 months after first DMH injection. The
exposure to melatonin was followed by the decrease of intestinal
tumor incidence in jejunum and ascending colon as compared to
controls. Melatonin inhibits multiplicity and size of colon tu-
mors as well as increases tumor differentiation. The level of
immunohistochemically detected melatonin in epithelium of the
intestinal tract of rats exposed to DMHwas significantly reduced
as compared to intact rats, while in rats treated with DMH+
melatonin it was in control ranges [147]. In the serum of rats
exposed to DMH alone the levels of diene conjugates (DC) and
Schiff's bases (SB) were significantly increased as compared
with controls. In colon tissue of DMH-treated rats the levels of
DC, SB, carbonyl derivatives of amino acids NO-synthase
activity were significantly increased and total antioxidative acti-
vity was decreased as compared to controls. In rats exposed to
DMH+melatonin a normalization of free radical processes in
serum and colon has been observed [146]. MLT also inhibits the
mutagenic effect of DMH in vivo (chromosome aberration and
sperm head anomalities tests) and in vitro (Ames' test). Mela-
tonin also exerts some normalizing influence on glucose and
lipid metabolism in rats exposed to DMH and inhibits proli-
feration and stimulates apoptosis in DMH-induced colon tumors
[148].In experiments of Weisburger et al. [149], male F344 rats
were injected subcutaneously with an aqueous solution of
15 mg/kg azoxymethane on day 50 and day of 57, and a group
was also given the 0.5 mgmelatonin solution 5 times per week at
4:30 pm. Controls were handled identically without melatonin.
The rats given azoxymethane were examined for foci of aberrant
crypts in the colon after 8 weeks of test. In rats given azoxy-
methane and the melatonin injections, there were fewer foci of
aberrant crypts in the colon and the average number of crypts
was fewer as well.
DLD-1 human colon carcinoma cells were insensitive to high
concentrations of melatonin (10−4 M) [112]. Using the CaCo-2
human colon carcinoma cell line Pentney [150] failed to observe
an antiproliferative effect of melatonin in physiological
concentrations. The only effect occurred at suprapharmacologi-
cal concentrations (10−3 M). Thus, these data have shown that
melatonin affect initiating, promoting and, in less degree, prog-
ression stages of colon carcinogenesis.
8.3. Melatonin and cervico-vaginal carcinogenesis
In our experiments, forty female CBAmice aged 3–4 months
were exposed twice a week during 2 months to intravaginal
applications of polyurethane sponges impregnated with 0.1%
solution of DMBA in triethyleneglycol [151]. Three hours after
each application the sponges were taken out. Starting from the
day of the 1st DMBA application a part of mice was exposed five
time a week during 4 months with melatonin in tap water (20 μg/
ml) given at night time. All mice were sacrificed in 6 months
after start of the experiment. Seven of 20 mice exposed to
DMBA alone developed malignancies in the vagina and cervix
uteri and two mice developed benign cervical tumors. No malig-
nancies in vagina and uterine cervix and three vaginal papil-
lomas were observed in mice exposed to DMBA+melatonin.
Thus, these data indicate that melatonin inhibits cervical and
vaginal carcinogenesis induced by DMBA in mice.
8.4. Melatonin and endometrial carcinogenesis
Experiments with spontaneous endometrial carcinomas in
BDII/Han rats have shown that melatonin prolonged survival of
rats only if chronic night-time administration in drinking water
was initiated by day 30 of life [152], i.e., shortly before begin-
ning of puberty, whereas life-long treatment was ineffective if
treatment was started on day 50, when animals had attained
puberty [153]. Since the pineal hormone delays pubertal deve-
lopment in bothmale and female rats it can be anticipated that the
action of melatonin on endometrial cancer is exerted by delaying
reproductive maturation [115].
8.5. Melatonin and hepatocarcinogenesis
Six-week-old male F344 rats were given a single dose of N-
diethylnitrosamine (DENA, 200 mg/kg b.w., i.p.). Starting
2 weeks later, there were treated with 0, 1, 5, 10 and 20 ppm
melatonin in their night drinking water for 6 weeks [154]. At
week 8, the experiment was terminated and the animals were
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both numbers and areas of glutathione S-transferase (GST-P)-
positive liver foci, liver preneoplastic lesions, in the liver were
decreased in the melatonin treated groups, this being significant
for the number in the 10 ppm melatonin group. Administration
of melatonin reverted the DENA induced alteration in GSH and
GSH related enzyme activities in the liver [155] and inhibited
DENA induced hepatocarcinogenesis in male Wistar rats [156].
Sugie et al. [157] reported that melatonin inhibited development
of hepatocellular adenomas and adenocarcinomas induced by
DENA and phenobarbital inn both initiation and promotion
phases of carcinogenesis.
Blask et al. [158] have shown that both physiological and
pharmacological levels of melatonin exhibit substantial antican-
cer activity in tissue isolated rat hepatoma 7288 CTC via
melatonin receptor-mediated blockade of tumor uptake of lino-
leic acid and its metabolism to the mitogenic signaling molecule
13-hydroxyoctadecadienoic acid. Melatonin receptor antagonist
S20928 completely blocked the effects and prevented the intra-
tumoral accumulation of melatonin.
8.6. Melatonin and lung carcinogenesis
Female A/J were injected subcutaneously with a single dose
of urethane at 49 days of age and injected with 0.1 mg melatonin
solution in aqueous ethanol 5 times per week [149]. The mice
given urethane and melatonin displayed insignificantly fewer
pulmonary tumors, than the controls on urethane alone, after an
18 week period.
In our experiments, SHR/u mice at the age of 3 months were
given a single i.p. injection of 1 mg/kg urethane and a part of
mice was exposed to melatonin (2 or 20 μg/ml) in night drinking
water [159]. At the 28 week after the injection of the carcinogen
the experiment was terminated. The number of lung adenomas
was 23±2.63 per mouse in the groups treated with urethane
alone, 11±0.72 in the group exposed to lower dose of urethane
and 14±1.2 in the group treated with 20 μg/mlmelatonin. Serum
malonic dialdehyde level was increased by 62% inmice exposed
to urethane alone as compared to intact mice, whereas treatment
with both doses of melatonin decreased serum MDA level in
urethane treated animals.
8.7. Melatonin and skin carcinogenesis
The effect of melatonin on benzo(a)pyrene (BP)-induced two
stage skin carcinogenesis in mice was evaluated [160]. It was
observed that it cannot only decrease the number of animals
bearing papillomas but also the number of papillomas per animal
both in the initiation and promotion stages of skin carcinogen-
esis. It was also found that melatonin treated animals have low
levels of lipid peroxides and that it can also prevent the binding
of BP or its metabolites to DNA.
8.8. Melatonin and carcinogenesis in subcutaneous tissues
Daily melatonin injections (50 μg/day) following the induc-
tion of fibrosarcomas in DBF1 mice with 3-methylcholanthreneresults in a suppression of tumorigenesis during the early stages
of carcinogenesis [161].
Three-month-old Swiss-derived SHR/u mice were subcuta-
neously injected with 2 mg of BP dissolved in 0.1 ml of olive oil.
After the injections of the carcinogen two groups of mice were
given melatonin with night drinking water at the doses of 2 mg/
l or 20 mg/l and one group of mice was not treated with
melatonin and served as a control [162]. at the 28th week after
the carcinogen administration the experiment was stopped and
animals were sacrificed. the results show that melatonin treat-
ment inhibits BP-induced carcinogenesis, decreases the inci-
dence of subcutaneous sarcomas, increases their latency and
survival of mice. the level of MDA in the serum of BP-induced
tumor-bearing mice was increased 2.6 times (p<0.01) and in the
tumors was increased by 11.1% (p<0.01) as compared to intact
control mice. treatment with melatonin significantly decreased
the level MDA both in the serum and in the tumor tissue. the
activity of catalase in the serum of BP-induced tumor-bearing
mice was increased by 12.1% as compared to the intact control
mice (p<0.01) and was unchanged in the tumor tissue. treatment
with melatonin at the dose 2mg/l significantly decreased activity
of catalase in the serum (by 31.7%, p<0.01) and in the tumor
tissue (by 2.6 times, p<0.01) as compared to the animals treated
with BP alone. thus it was shown inhibitory effect of melatonin
on malignancies of mesenchymal origin induced by BP, and
have shown that the lower dose of melatonin appeared to be
more effective in the inhibition of lipid peroxidation and tumor-
igenesis induced by chemical carcinogen than higher one.
In Table 3, we summarized available data on effect of mela-
tonin on carcinogenesis.
8.9. Effect of melatonin on transplantable tumors in vivo and
tumor growth in vitro
There are a number reports on inhibitory effect of melatonin
on the growth of tumors in vitro (Table 4) and growth tran-
splantable tumors of different histogenesis in vivo (for review
see [113,115,163]).
8.10. Effect of melatonin in cancer patients
The results of clinical application of melatonin in cancer
patients comprehensively reviewed in several recent publica-
tions [113–115,164–166,183–185].Mills et al. [17] conducted a
systematic review of 10 randomized controlled trials of
melatonin in solid cancer patients and its effect on survival at
1 year. The reports included totally 643 patients. It was shown
that melatonin reduced the risk of death at 1 year (relative risk:
0.66, 95% CI=0.59–0.73). Effects were consistent across
melatonin dose, and type of cancer. It is worthy to note that no
severe adverse events were reported.
9. Effect of melatonin effects on glucose and lipid
metabolism
The insulin/insulin-like growth factor-1 (IGF-1) signaling
pathway plays a fundamental role in animal physiology,
Table 3
Summary on anticarcinogenic effect of melatonin in rodents
Target tissue Tumor type Strain Carcinogen References
Mice
Mammary gland Adenocarcinoma SHR Spontaneous [103]
C3H/Jax MMTV [98]
ras-MMTV-LTR a [141]
TG.NK MMTV/c-neua [142]
FVB/N HER-2/neua [143]
Uterine cervix and vagina Squamous-cell papilloma
and carcinoma
CBA DMBA [151]
Skin Papilloma Swiss Benzo[a]pyrene+croton oil [160]
Subcutaneous tissue Sarcoma DBF1 3-Methylcholanthrene [161]
SHR/u Benzo[a]pyrene [117]
Lung Adenoma A/J Urethane [149]
SHR/u Urethane [162]
Rats
Mammary gland Mastopathy Outbred Spontaneous [107,186]
Adenocarcinoma Sprague–Dawley; Holzman DMBA [128,129,134,135]
Sprague–Dawley; LIO NMU [130,131,137,187]
Wistar:Han γ-rays+DMBA [188]
Liver Preneoplastic liver foci
(GST-positive)
F344 DENA [154]
Hepatocarcinoma Wistar DENA [155–157]
Endometrium Adenocarcinoma BDII/Han Spontaneous [153]
Colon Adenocarcinoma LIO DMH [145]
Foci of aberrant crypts F344 Azoxymethane [149]
a Transgenic mice.
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species [189,190]. Despite a large number of studies, the role of
melatonin on glucose metabolism is rather controversial. There
are reports that a lack of melatonin has effects on the action of
insulin in rats [191], on the stimulation of blood glucose and
insulin levels in rats [192], and causes a marked decrease of
insulin secretion by rat pancreatic islets in response to glucose in
vitro [193]. In postmenopausal women, the oral administration
of 1 mg of melatonin reduced glucose tolerance and insulin
sensitivity [194]. Melatonin administration at middle age de-
creased visceral fat, plasma insulin and IGF-1 levels in rats
[195]. It also enhanced the utilization of liver carbohydrates but
suppressed hepatic lipolysis [196]. Long-term treatment with
melatonin reduced hyperinsulinemia, hypertriglyceridemia,
hyperleptinemia and restored hepatic delta-5 desaturase activity
in type 2 diabetic rats [197]. The administration of melatonin to
normal rats resulted in significant decreases in serum leptin
levels compared to those of control animals, whereas a pinea-
lectomy significantly increased it level [198]. Melatonin sig-
nificantly augmented the level of total, free, and esterified
cholesterol, as well as high-density lipoprotein cholesterol in rat
blood [192]. Supplementation of the diet with melatonin led to
an increase in the surface area of atherosclerotic lesions in the
proximal aorta of hypercholesterinemic mice and increased the
susceptibility to ex vivo oxidation of atherogenic lipoproteins
isolated from the plasma during the fasting period [28]. How-
ever, there are reports on the inhibitory effect of high doses of
melatonin on the oxidation of low density lipids in rodents and
humans [199,200]. Thus, these observations suggest that caution
should be taken with high melatonin dose supplementation.Further investigations should be performed on animals and
humans to clarify the effect of melatonin on carbohydrate and
lipid metabolism.
10. Effect of melatonin on immune system
Immunopharmacological activity of melatonin has been
demonstrated in various experimental models [201–203]. In
1986, Maestroni et al. [204] first showed that inhibition of
melatonin synthesis causes inhibition of cellular and humoral
responses in mice. Melatonin receptors are detectable in
monocyte/macrophage lineage and melatonin binding to these
receptors stimulates the production of GMCFU cells [203].
Melatonin stimulates the production of progenitor cells for gra-
nulocytes and macrophages (GM-CFU) and has a general
stimulatory action on hemopoiesis [201–203]. The action of
melatonin on monocyte production can be partly due to its direct
action on melatonin receptors or may be due to an increase of
monocyte sensitivity to stimulants like IL-3, IL-4, IL-6 or GM-
colony stimulating factor (GM-CSF).
Treatment with melatonin increases production of antibodies
to sheep erythrocytes and immune response to primary immu-
nization with T-dependent antigen [205]. There is evidence of an
involvement of melatonin in complex relationships between
nervous and endocrine system [201,206,207]. There are mela-
tonin membrane receptors on Ò-helpers (Th). Activation of
melatonin receptors leads to the increase of release of some type
Th1 cytokines, including γ-interferon, interleukin-1 and opioid
cytokines related to interleukin-4 and dinorphine [201,207].
Melatonin stimulates production of interleukines-1, -6 and -12 in
Table 4
Effect of melatonin on tumor growth in vitro
Tumor strain Effective dose
of melatonin
Effect of
melatonin
References
Human breast carcinoma
MCF-7
1 nM ↓ [121,164]
Murine melanoma M2R 0.1–10 nM ↓ [165]
Murine melanoma B16 10−3 M ↓ [166]
Hamster melanoma B7 μM ↓ [167]
Human melanoma μM ↓ [168]
Primary human melanoma
cell line
0.001 pm–10 μM ↓ [169]
Ovarian carcinomas
SK-OV-3 and JA-1
mM ↓ [170]
Human serose
cystadenocarcinoma KF
200 μM ↑ [171]
Ovarian carcinomaEFO-27 0.1 mM–0.1 pM ↓ [172]
Human endometrial
carcinoma RL95-2
mM ↓ [173]
1 nM =
Human cervical carcinoma
HeLa
<1 nM = [174,175]
100 μM ↓
Human cervical carcinoma
ME-180
2 μM = [176]
2 mM ↓
Trophoblastic tumor JAR 4–500 μM ↓ [177]
Human prostate cell line
LNCaP
mM ↓ [178]
Hamster transplantable
hepatoma
mM = [175]
Human neuroblastoma
SK-N-SH
10 pM–1 nM ↓ [164]
Rat pituitary prolactinoma 0.1 μM–10 pM ↓ [179]
Rat DES–induced
prolactinoma
10−7–10−11 M ↓ [112]
Human epidermoid
carcinoma
<1 mM = [174]
Human colon carcinoma
DLD-1
10−4 M = [112]
Human colon carcinoma
CaCo-2
10−3 M ↓ [150]
Human transition-cell
bladder carcinoma
RT112
0.5 mM ↓ [180]
Rat pheochromocytoma
PC12
1–10 nM ↓ [181]
10 μM ↑
Erhythroleukemia K562 MM ↓ [172]
Sarcoma-180 MM Weak
effect
[177]
Murine lymphoid tumor MM Weak
effect
[177]
Human myeloma 200 μM ↑ [182]
Human lymphoblastoid
TK6 cells
0.1 μM–0.1 nM = [175]
Human osteogenic sarcoma
MG-63
0.1 μM–0.1 nM = [175]
Note: ↓ — inhibition; ↑ — stimulation; = — no effect.
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immunodepression defending mice from virus- and bacteria-
induced lethal disease [207]. Important chain in mechanism of
influence of melatonin on hemopoiesis includes the effect of
melatonin-induced opioids on κ-opioid receptors at stromal
macrophages of bone marrow [207]. It is worthy to note, that γ-
interferon and colony-stimulating factors (CSFs) can modulate a
production of melatonin in the pineal gland [207]. The loss of
thymocytes with age is the main cause of structural thymicatrophy and thymic weight loss. Treatment with melatonin
inhibits apoptosis in thymocytes and increased their total
number in old mice [208,209]. The reversal of age-associated
thymic involution by melatonin added further support to the
concept that melatonin can be a potential therapeutic agent for
correcting immunodeficiency state associated with aging and
possibly other immunocompromised states like severe stress
[203]. Thus, melatonin it was shown has rather immunostimu-
latory potential.
11. Conclusion
The analysis of available data on the effect of melatonin on
longevity support the hypothesis of a geroprotective effect of
melatonin. At the same time, a critical review of real results has
shown that the majority of studies are invalid when considering
the current guidelines for long-term testing of chemicals for
carcinogenic safety [15,16] and, to some extent, from the point
of view of the correctness of the gerontological experiment. In
some experiments, melatonin was given to a small number of
animals (from 10 to 20); the treatments started when the animals
were old; the observations were stopped when the animals
reached 50% mortality or at some other arbitrary time, but not at
the natural death of the last survivor; an autopsy and correct
pathomorphological examination was not always performed; the
body weight and food consumption of the animals were not
monitored; and so on. We believe that the study of long-term
effects of melatonin at a variety of doses in different strains
and species (e.g., in rats) will be useful for making a con-
clusion on its safety. In adequately designed experiments (50
animals per group), melatonin given during the night time in
relatively small doses (2.5–3 mg/kg) delayed the onset of age-
related disturbances in estrous function and increased survival
of animals.
There is evidence on suppressive effect of melatonin on the
development of spontaneous and chemically induced carcino-
genesis at various sites in mice and rats as well as on the tumor
growth in vitro. There are also observations of positive effect of
melatonin in the treatment of advanced cancer patients
[17,163,212]. Thus, melatonin is a potent geroprotector, antic-
arcinogen and antitumor compound. The results of the clinical
administration of melatonin are promising [17,210–212].
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